Puma Biotechnology (PBYI) vs Phathom Pharmaceuticals (PHAT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Puma Biotechnology (PBYI) has outperformed Phathom Pharmaceuticals (PHAT) over the past year, gaining 44.2% versus a loss of 68.9%. Over five years, PBYI leads with a +118.3% price change compared with -76.5% for PHAT. Phathom Pharmaceuticals is the larger company by market cap ($378.8 million vs $364.5 million), about 1.0 times the size.
On valuation, Phathom Pharmaceuticals trades at a lower forward P/E (5.2x vs 20.1x for Puma Biotechnology). Puma Biotechnology converts more of its revenue into profit, with a net margin of 13.6% versus -126.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PBYI | PHAT |
|---|---|---|
| Share price | $7.05 | $4.66 |
| Market cap | $364.47M | $378.82M |
| 1-day change | -0.98% | -8.27% |
| YTD return | +18.49% | -71.91% |
| 1-year return | +44.17% | -68.93% |
| 5-year return | +118.27% | -76.46% |
| P/E ratio (TTM) | 15.33 | — |
| Forward P/E | 20.14 | 5.18 |
| EPS (TTM) | $0.46 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $228.37M | $175.11M |
| Revenue growth (YoY) | -0.91% | +216.93% |
| Net income (latest FY) | $31.11M | $-221.25M |
| Gross margin | 74.53% | 87.09% |
| Operating margin | 16.33% | -91.36% |
| Net margin | 13.62% | -126.35% |
| 52-week high | $11.50 | $18.31 |
| 52-week low | $4.84 | $4.62 |
| Distance from 52-week high | -38.70% | -74.55% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | — | +321.67% |
| Average volume | 387.40K | 1.45M |
| Shares outstanding | 51.70M | 81.29M |
| Employees | 179 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PBYI has outperformed PHAT by 113.1 percentage points over the past year.
- Puma Biotechnology is more profitable, keeping 13.6 cents of every revenue dollar as net income versus -126.3 cents for Phathom Pharmaceuticals.
- Phathom Pharmaceuticals grew revenue faster in its latest fiscal year (+216.93% vs -0.91%).
About Puma Biotechnology
PBYI stock →Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Health Care · Biotechnology: Pharmaceutical Preparations · 179 employees
About Phathom Pharmaceuticals
PHAT stock →Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
Health Care · Biotechnology: Pharmaceutical Preparations · 371 employees
PBYI vs PHAT FAQ
Which is bigger, Puma Biotechnology or Phathom Pharmaceuticals?
Phathom Pharmaceuticals (PHAT) is larger, with a market capitalization of $378.82M compared with $364.47M for Puma Biotechnology (PBYI).
Which stock has performed better over the past year, PBYI or PHAT?
PBYI returned +44.17% over the past 12 months, compared with -68.93% for PHAT (price return, excluding dividends). Past performance does not predict future results.
Are Puma Biotechnology and Phathom Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.